STAG2 mutation predicts superior posttransplant survival in acute myeloid leukemia treated with low-intensity induction - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

STAG2 Mutation Is Associated With Improved Posttransplant Survival in Acute Myeloid Leukemia After Low-Intensity Induction

  • By

  • Yu-Sung Chang

  • Hsin-An Hou

  • October 31, 2026

Share

  • 1

    In this 46-patient cohort, six patients had STAG2 mutations, and none died during a median follow-up of 34.7 months.

  • 2

    Two-year overall survival was 100% with STAG2 mutations and 39.2% with wild-type STAG2 (P = .028).

  • 3

    Age and DNMT3A mutation were not associated with overall survival, and the three-tier composite score did not stratify survival (P = .42).

  • 4

    The cohort included varied low-intensity induction regimens; five of six patients with STAG2 mutations received venetoclax plus low-dose cytarabine.

  • 5

    Because only one patient with a STAG2 mutation received venetoclax-free therapy, the study could not distinguish venetoclax sensitivity from intrinsically favorable disease biology.

Original Source(s)

STAG2 mutation predicts superior posttransplant survival in acute myeloid leukemia treated with low-intensity induction

  • by Yu-Sung Chang, Hsin-An Hou

  • October 31, 2026

Related Content

Prime Editing Corrects GATA2 Deficiency in Patient Stem Cells

The double-strand break-free approach increased functional GATA2 alleles and improved the engraftment of edited blood stem cells in mice

  • October 21, 2026

  • 3 min
Retroperitoneal Spindle Cell Liposarcoma Presenting With Bowel Obstruction

  • October 20, 2026

Correction: Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study on behalf of the EBMT acute leukemia working party